By: Robert Mittendorff, MD, Adam Seabrook, Nick Whitehead, Athena Shea, and Keegan McGuire
B Capital is proud to partner with Cadence, a health technology company building AI-enabled, continuous care for the tens of millions of Americans living with chronic disease. The investment was led by General Partner, Robert Mittendorff, MD, MBA, alongside Adam Seabrook, Nick Whitehead, Athena Shea, and Keegan McGuire.
Cadence pairs a physician-led care team with a clinical AI platform embedded in leading health systems’ EMRs to manage patients between visits, where we believe chronic disease is actually won or lost.
Care is Currently Built for Episodes, but Disease Progression Never Stops
American primary care is still organized around the scheduled office visit, a model mismatched to a Medicare population dominated by chronic conditions like hypertension, heart failure, and diabetes. The highest-risk windows in a patient’s life are the ones the episodic model can’t see, including the weeks between appointments and the fragile days after a hospital discharge. In these gaps, disease quietly worsens, medications go unadjusted, and small problems escalate into avoidable hospitalizations.
RPM and APCM are Foundations for Longitudinal Care
The payment infrastructure to fund continuous care now exists. The Centers for Medicare & Medicaid Services (CMS) has created two complementary, recurring programs that, together, fund a continuous care relationship and a chassis an AI-enabled chronic care company can build on.
- Remote Patient Monitoring (RPM) extends the clinical encounter into the patient’s daily environment through continuous physiological data capture, enabling care teams to intervene before a threshold event. Clinicians bill monthly for managing data streamed from FDA-cleared home devices.
- Advanced Primary Care Management (APCM) ensures a designated primary care provider actively coordinates a patient’s health across all settings, with structured access to the care team around the clock. It pays a fixed monthly fee based on clinical complexity rather than logged minutes, rewarding availability of care and enabling technology-assisted delivery at scale.
Together, RPM and APCM create the continuous care infrastructure to lower total costs at scale for Medicare. RPM supplies the real-time signal, and APCM funds the around-the-clock relationship that acts on these signals. Cadence’s early outcomes suggest this model can reduce avoidable utilization meaningfully, saving Medicare $2.7M per week today. Given chronic disease and avoidable hospitalizations are the largest cost drivers to Medicare, continuous AI-enabled care that improves outcomes is an opportunity worth tens of billions per year. Penetration is still in the low single digits, representing a large, durable, federally supported market compounding with an aging population.
AI Turns the RPM and APCM Chassis into a Scalable Care Model
The hurdle for effective longitudinal care has always been the scalability of clinical teams to perform monitoring, triage, coordination, and medication management for large patient panels.
This is where Cadence’s investment in AI excels. Its Clinical Intelligence layer automates the predictable and escalates the complex, while keeping physicians firmly in control. It identifies risk early from vitals, symptoms, medications, and engagement signals, then equips the care team to act with full clinical context and safety guardrails. Purpose-built agents handle specific workflows, surfacing protocol-driven titration opportunities for clinician review, responding first to out-of-range readings, coordinating care, supporting lifestyle change, all under clinician oversight.
The result is leverage, enabling existing teams safely manage far larger patient panels, expanding patient access. Cadence reports it returned roughly 85,000 clinician hours to partner systems in a year, supported 24,000 medication titrations in 2025, and resolved 99% of alerts without physician escalation. The key question in this category is whether AI collapses the cost of delivering continuous care and Cadence’s early data suggests the answer is yes.
The Proof is in the Outcomes
What separated Cadence in diligence was its peer-reviewed evidence base, which is unusual for a company of its age:
- JACC: Advances (July 2025): more than 23,000 patients (57% in rural or underserved areas) with durable engagement and meaningful blood pressure reduction across geographies.
- NEJM Catalyst (October 2025): roughly $203 in monthly savings per patient, a 43% increase in blood pressure control, and a 107% increase in heart-failure patients on all four pillars of guideline-directed therapy.
- Mayo Clinic Proceedings (December 2025): a $1,302 per-patient-per-year reduction in total cost of care, driven primarily by a $1,428 reduction in inpatient spend, with a 27% reduction in hospital admissions.
We believe these outcomes are the foundation of a durable moat.
The Team to Lead the Path Forward
Cadence’s founders, including Chris Altchek (CEO) and Eric Hauser (CTO), have assembled a clinical and operating organization with deep healthcare and technology experience. We are proud to back Chris, Eric, and the entire Cadence team as they build the definitive AI-enabled platform for longitudinal chronic care, and we look forward to partnering with them on the journey ahead.
LEGAL DISCLAIMER
All information is as of June 17, 2026 and subject to change. This content is a high-level overview and for informational purposes only. The investment discussed herein is a portfolio company of B Capital; however, such investment does not represent all B Capital investments. Certain statements reflected herein reflect the subjective opinions and views of B Capital personnel. Such statements cannot be independently verified and are subject to change. There can be no assurance any such trends or correlations will continue in the future. Reference to third-party firms or businesses does not imply affiliation with or endorsement by such firms or businesses. It should not be assumed that any investments or companies identified and discussed herein were or will be profitable. Past performance is not indicative of future results. The information herein does not constitute or form part of an offer to issue or sell, or a solicitation of an offer to subscribe or buy, any securities or other financial instruments, nor does it constitute a financial promotion, investment advice or an inducement or incitement to participate in any product, offering or investment. Much of the relevant information is derived directly from various sources which B Capital believes to be reliable, but without independent verification. This information is provided for reference only and the companies described herein may not be representative of all relevant companies or B Capital investments. You should not rely upon this information to form the definitive basis for any decision, contract, commitment or action. Any forward-looking statements are based solely on information provided by the company or on publicly available data and reflect the views of the authors as of the date of publication. B Capital is not making any guarantees with respect to any such forward-looking information.